PMID- 28651294
OWN - NLM
STAT- MEDLINE
DCOM- 20190508
LR  - 20190508
IS  - 1438-8790 (Electronic)
IS  - 0934-8387 (Linking)
VI  - 71
IP  - 6
DP  - 2017 Jun
TI  - [IgE and Anti-IgE in Asthma: A Chequered History].
PG  - 398-405
LID - 10.1055/s-0043-102070 [doi]
AB  - A long and winding road led to the discovery of immunoglobulin E (IgE) in 1966 
      and 1967. We are currently on a long and winding road to understand the 
      immunologic basis of the clinical effects of the anti-IgE antibody omalizumab in 
      asthma. It is possible that patients with asthma (as patients with chronic 
      spontaneous urticaria) benefit in different immunologic ways from omalizumab 
      treatment. This article reviews the history of IgE discovery and current concepts 
      of anti-IgE therapy in asthma.
CI  - (c) Georg Thieme Verlag KG Stuttgart . New York.
FAU - Lommatzsch, M
AU  - Lommatzsch M
AD  - Abteilung fur Pneumologie/Interdisziplinare Internistische Intensivstation, 
      Zentrum fur Innere Medizin, Universitat Rostock.
FAU - Geissler, K
AU  - Geissler K
AD  - Abteilung fur Pneumologie/Interdisziplinare Internistische Intensivstation, 
      Zentrum fur Innere Medizin, Universitat Rostock.
FAU - Bergmann, K-C
AU  - Bergmann KC
AD  - Allergie-Centrum der Charite, Klinik fur Dermatologie, Venerologie und 
      Allergologie, Charite - Campus Mitte, Berlin.
FAU - Virchow, J Christian
AU  - Virchow JC
AD  - Abteilung fur Pneumologie/Interdisziplinare Internistische Intensivstation, 
      Zentrum fur Innere Medizin, Universitat Rostock.
LA  - ger
PT  - Historical Article
PT  - Journal Article
PT  - Review
TT  - IgE und Anti-IgE bei Asthma: eine wechselvolle Geschichte.
DEP - 20170626
PL  - Germany
TA  - Pneumologie
JT  - Pneumologie (Stuttgart, Germany)
JID - 8906641
RN  - 0 (Anti-Asthmatic Agents)
RN  - 0 (Antibodies, Anti-Idiotypic)
RN  - 0 (anti-IgE antibodies)
RN  - 37341-29-0 (Immunoglobulin E)
SB  - IM
MH  - Anti-Asthmatic Agents/*history/therapeutic use
MH  - Antibodies, Anti-Idiotypic/*history
MH  - Asthma/drug therapy/*history
MH  - Europe
MH  - History, 17th Century
MH  - History, 18th Century
MH  - History, 19th Century
MH  - History, 20th Century
MH  - History, 21st Century
MH  - Humans
MH  - Immunoglobulin E/*history
MH  - United States
COIS- Interessenkonflikt: M. Lommatzsch erhielt Honorare fur Beratungen und Vortrage 
      von den Firmen ALK Abello, Allergopharma, AstraZeneca, Bencard, Berlin-Chemie, 
      Boehringer-Ingelheim, Boston Scientific, Chiesi, GSK, Janssen-Cilag, MSD, 
      Mundipharma, Novartis, Nycomed/Takeda, Sanofi, TEVA, UCB. ML erhielt 
      Forschungsforderung von der Deutschen Forschungsgemeinschaft (DFG), dem Land 
      Mecklenburg-Vorpommern, GSK, AstraZeneca. K. Geissler hat Vortragshonorare von den 
      Firmen AstraZeneca, Novartis und Teva erhalten. KG hat Forschungsforderung von 
      den Firmen AstraZeneca und Teva erhalten. K.-C. Bergmann hat Vortrags- und 
      Beraterhonorare von den Firmen AstraZeneca, ALK, Bencard, HAL, Lofarma, Novartis, 
      Stallergenes und Teva erhalten. J. C. Virchow hat Vortrage gehalten und Honoraria 
      erhalten von: AstraZeneca, Avontec, Bayer, Bencard, Bionorica, 
      Boehringer-Ingelheim, Chiesi, Essex/Schering-Plough, GSK, Janssen-Cilag, Leti, 
      MEDA, Merck, MSD, Mundipharma, Novartis, Nycomed/Altana, Pfizer, Revotar, 
      Sanofi/Regeneron, Sandoz-Hexal, Stallergens, TEVA, UCB/Schwarz-Pharma, 
      Zydus/Cadila und als Berater fungiert fur: Avontec, Boehringer-Ingelheim, Chiesi, 
      Essex/Schering-Plough, GSK, Janssen-Cilag, MEDA, MSD, Mundipharma, Novartis, 
      Regeneron, Revotar, Roche, Sanofi-Aventis, Sanofi/Regeneron, Sandoz-Hexal, TEVA, 
      UCB/Schwarz-Pharma. JCV hat Forschungsforderung erhalten von der Deutschen 
      Forschungsgemeinschaft (DFG), dem Land Mecklenburg-Vorpommern, GSK, MSD.
EDAT- 2017/06/27 06:00
MHDA- 2019/05/09 06:00
CRDT- 2017/06/27 06:00
PHST- 2017/06/27 06:00 [entrez]
PHST- 2017/06/27 06:00 [pubmed]
PHST- 2019/05/09 06:00 [medline]
AID - 10.1055/s-0043-102070 [doi]
PST - ppublish
SO  - Pneumologie. 2017 Jun;71(6):398-405. doi: 10.1055/s-0043-102070. Epub 2017 Jun 
      26.